Genmab develops fully human, high affinity antibodies to treat life-threatening and debilitating diseases. Some of our HuMax antibodies have been shown to be 100 to 1000 times better at finding and binding to their disease target than earlier generations of murine or laboratory-engineered antibodies which are not fully human. In addition, we believe that fully human antibody therapies may have other advantages over older generation products, such as a more favorable safety profile and improved treatment regimens.

A number of Genmab's antibodies are currently available for licensing. Click on each product for more information.

Zalutumumab - oncology
A fully human antibody targeting EGFr, a validated tumor target.

HuMax-IL8 - autoimmune disease and oncology

Initial clinical studies show this antibody to be safe, well-tolerated and biologically active. A CHO-GS cell line, and cell bank, is ready for production. 

HuMax-HepC - infectious disease
An IND-ready antibody for the prevention of HCV reinfection in liver transplant recipients. 

HuMax-TAC - autoimmune disease, oncology, organ transplantation

Recent preclinical data demonstrate improved properties over existing therapies. A potential bio-better in Multiple Sclerosis. 

Genmab's UniBody technology is also available for licensing.

For more information on licensing opportunities at Genmab, please contact our Business Development department at licensing@genmab.com.